The second stage of clinical trials for a domestic antitumor drug, developed by scientists from Nazarbayev University, has commenced in Kazakhstan. In the initial stage of the experiment, the drug demonstrated its effectiveness, successfully reducing tumors by an average of 30% in 15 subjects diagnosed with stage four colon cancer. This was announced by the country’s Minister of Science and Higher Education, Sayasat Nurbek.
“By the end of the year we will process all the data. We hope that next year we will launch the medicine for registration,” Nurbek emphasized.
The second stage of the study will involve 3,000 people with various types of cancer, and over 5,000 cancer patients have shown interest in participating in the trial. The tests will take place in Astana, Almaty, and Pavlodar, requiring approximately 2 billion tenge (~370 million rubles) – with the decision on fund allocation having already been made by the Higher Scientific and Technical Commission.
